Inherited susceptibility for aggressive prostate cancer

Asian Journal of Andrology

Volumn 14, Issue 3, 2012, Pages 415-418

  Isaacs, William B ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

aggressiveness; Genome Wide Association Studies; germline; GWAS; inherited; linkage; mutation; single nucleotide polymorphisms; SNPs; susceptibility

Indexed keywords

ASIA; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; DIZYGOTIC TWINS; ENVIRONMENTAL FACTOR; FAMILIAL CANCER; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; INHERITANCE; MONOZYGOTIC TWINS; PROSTATE CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

DISEASE PROGRESSION; DNA, NEOPLASM; FAMILY HEALTH; GENETIC LINKAGE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84860870211     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.146     Document Type: Review

References (59)

1. Johns LE, Houlston RS. A systematic review and meta-Analysis of familial prostate cancer risk. BJU Int 2003; 91: 789-794. (Pubitemid 36724060)
2. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J et al. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85. (Pubitemid 30451850)
3. Shuen AY, Foulkes WD. Inherited mutations in breast cancer genes-risk and response. J Mammary Gland Biol Neoplasia 2011; 16: 3-15. Review.
4. Langeberg WJ, Isaacs WB, Stanford JL. Genetic etiology of hereditary prostate cancer. Front Biosci 2007; 12: 4101-4110.
5. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012; 366: 141-149.
6. Schork NJ, Murray SS, Frazer KA, Topol EJ. Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev 2009; 19: 212-219.
7. http://www.genome.gov/gwastudies/Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39: 631-637. (Pubitemid 46676102)
8. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977-983. (Pubitemid 47185170)
9. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-315. (Pubitemid 351311773)
10. Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008; 40: 281-283. (Pubitemid 351311771)
11. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, GuyMet al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40: 316-321. (Pubitemid 351311772)
12. Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99: 1836-1844. (Pubitemid 351767196)
13. Easton DF, Eeles RA. Genome-wide association studies in cancer. Hum Mol Genet 2008; 17: R109-15.
14. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910-919. (Pubitemid 351397090)
15. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011; 43: 785-791.
16. Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G et al. Individual and cumulative effect of prostate cancer risk-Associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 2009; 69: 1195-1205.
17. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 2010; 183: 1792-1796.
18. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ et al. The influence of finasteride on the development of prostate cancer.NEngl J Med 2003; 349: 215-224. (Pubitemid 36859473)
19. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
20. Xu J, Sun J, Kader AK, Lindström S, Wiklund F, Hsu FC et al. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 2009; 69: 1565-1572.
21. Aly M, Wiklund F, Xu J, Isaacs WB, Eklund M, D'Amato M et al. Polygenic risk score improves prostate cancer risk prediction: Results from the Stockholm-1 cohort study. Eur Urol 2011; 60: 21-28.
22. Macinnis RJ, Antoniou AC, Eeles RA, Severi G, Al Olama AA et al. A risk prediction algorithm based on family history and common genetic variants: Application to prostate cancer with potential clinical impact. Genet Epidemiol 2011; 35: 549-556.
23. Gelmann EP. Complexities of prostate-cancer risk. N Engl J Med 2008; 358: 961-963. (Pubitemid 351397098)
24. Lindström LS, Hall P, Hartman M, Wiklund F, Grönberg H et al. Familial concordance in cancer survival: A Swedish population-based study. Lancet Oncol 2007; 8: 1001-1006. (Pubitemid 47629885)
25. Hemminki K. Familial risk and familial survival in prostate cancer. World J Urol; e-pub ahead of print 25 November; doi: 10.1007/s00345-011-0801-1.
26. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 1: 13 Spec No. 1: R103-21.
27. Ostrander EA, Kwon EM, Stanford JL. Genetic susceptibility to aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1761-1764. (Pubitemid 44664246)
28. Witte JS, Goddard KA, Conti DV, Elston RC, Lin J et al. Genomewide scan for prostate cancer-Aggressiveness loci. Am J Hum Genet 2000; 67: 92-99. (Pubitemid 30481547)
29. Goddard KA, Witte JS, Suarez BK, Catalona WJ, Olson JM. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet 2001; 68: 1197-1206. (Pubitemid 32424418)
30. Neville PJ, Conti DV, Paris PL, Levin H, Catalona WJ et al. Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. Neoplasia 2002; 4: 424-431. (Pubitemid 34976958)
31. Slager SL, Schaid DJ, Cunningham JM, McDonnell SK, Marks AF et al. Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet 2003; 72: 759-762. (Pubitemid 36255976)
32. Paiss T, Wörner S, Kurtz F, Haeussler J, Hautmann RE et al. Linkage of aggressive prostate cancer to chromosome 7q31-33 in German prostate cancer families. Eur J Hum Genet 2003; 11: 17-22. (Pubitemid 36175779)
33. Neville PJ, Conti DV, Krumroy LM, Catalona WJ, Suarez BK et al. Prostate cancer aggressiveness locus on chromosome segment 19q12-q13.1 identified by linkage and allelic imbalance studies. Genes Chromosomes Cancer 2003; 36: 332-339. (Pubitemid 36314516)
34. Stanford JL, McDonnell SK, Friedrichsen DM, Carlson EE, Kolb S et al. Prostate cancer and genetic susceptibility: A genome scan incorporating disease aggressiveness. Prostate 2006; 66: 317-325. (Pubitemid 43191231)
35. Chang BL, Isaacs SD, Wiley KE, Gillanders EM, Zheng SL et al. Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease. Prostate 2005; 64: 356-361. (Pubitemid 41193248)
36. Lange EM, Ho LA, Beebe-Dimmer JL, Wang Y, Gillanders EM et al. Genome-wide linkage scan for prostate cancer susceptibility genes in men with aggressive disease: Significant evidence for linkage at chromosome 15q12. Hum Genet 2006; 119: 400-407.
37. Slager SL, Zarfas KE, Brown WM, Lange EM, McDonnell SK et al. Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate 2006; 66: 173-179. (Pubitemid 43191238)
38. Christensen GB, Camp NJ, Farnham JM, Cannon-Albright LA. Genome-wide linkage analysis for aggressive prostate cancer in Utah high-risk pedigrees. Prostate 2007; 67: 605-613. (Pubitemid 46685280)
39. Schaid DJ, Stanford JL, McDonnell SK, Suuriniemi M, McIntosh L et al. Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q. Hum Genet 2007; 121: 729-735. (Pubitemid 46916972)
40. Liu X, Cheng I, Plummer SJ, Suarez BK, CaseyGet al. Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35. Prostate 2011; 71: 682-689.
41. Schaid DJ, McDonnell SK, Zarfas KE, Cunningham JM, Hebbring S et al. Pooled genome linkage scan of aggressive prostate cancer: Results from the International Consortium for Prostate Cancer Genetics. Hum Genet 2006; 120: 471-485. (Pubitemid 44669782)
42. Cicek MS, Conti DV, Curran A, Neville PJ, Paris PL et al. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 2004; 59: 69-76. (Pubitemid 38387844)
43. Casey G, Neville PJ, Liu X, Plummer SJ, Cicek MS et al. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet 2006; 15: 735-741. (Pubitemid 43264698)
44. Hayes VM, Severi G, Southey MC, Padilla EJ, English DR et al. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival. Cancer Epidemiol Biomarkers Prev 2006; 15: 1223-1225.
45. Huang SP, Huang CY, Wu WJ, Pu YS, Chen J et al. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer 2006; 119: 1902-1907. (Pubitemid 44356849)
46. Severi G, Hayes VM, Neufing P, Padilla EJ, Tilley WD et al. Variants in the prostatespecific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiol Biomarkers Prev 2006; 15: 1142-1147.
47. Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P et al. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: The hidden face of estrogens. J Clin Oncol 2007; 25: 3596-3602. (Pubitemid 47376605)
48. Siltanen S, Wahlfors T, Schindler M, Saramäki OR, Mpindi JP et al. Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells. PLoS ONE 2011; 6: E26595.
49. Sun T, Mary LG, Oh WK, Freedman ML, Pomerantz M et al. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res 2011; 17: 1546-1552.
50. Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL et al. Genetic variants in the LEPR, RY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancerspecific mortality. Cancer Epidemiol Biomarkers Prev 2011; 20: 1928-1936.
51. Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 2010; 103: 918-924.
52. Thorne H, Willems AJ, Niedermayr E, Hoh IM, Li J et al. Decreased prostate cancerspecific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res (Phila) 2011; 4: 1002-1010.
53. Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, CastroE et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients. Br J Cancer 2011; 105: 1230-1234.
54. Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010; 16: 2115-2121.
55. Penney KL, Pyne S, Schumacher FR, Sinnott JA, Mucci LA et al. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2010; 19: 2869-2876.
56. Nam RK, Zhang W, Siminovitch K, Shlien A, Kattan MW et al. New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. Cancer Biol Ther 2011; 12: 997-1004.
57. FitzGerald LM, Kwon EM, Conomos MP, Kolb S et al. Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 1196-1203.
58. Xu J, Zheng SL, Isaacs SD, Wiley KE, Wiklund F et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci USA 2010; 107: 2136-2140.
59. Jin G, Sun J, Liu W, Zhang Z, Chu LW et al. Genome-wide copy-number variation analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer. Carcinogenesis 2011; 32: 1057-1062.